سعر جليبوفين 5/850مجم 30 قرص 2025

Glybofen 5/850mg 30 f.c. tab: glibenclamide 5 mg + metformin 850 mg tablets (El Nile > Liptis), 30 tablets.

• Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Population: Adults with type 2 diabetesDailyMed (U.S. National Library of Medicine)

• Severe renal impairment (eGFR <30 mL/min/1.73 m²); hypersensitivity to metformin or glyburide; acute or chronic metabolic acidosis including diabetic ketoacidosis; concomitant bosentan.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: metformin-associated lactic acidosis (risk factors include renal impairment, age ≥65, iodinated contrast, surgery, hypoxic states, excess alcohol, hepatic impairment). Also severe hypoglycemia, possible increased cardiovascular mortality with sulfonylureas, hemolytic anemia in G6PD deficiency, and vitamin B12 deficiency.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• BosentanConcomitant use is contraindicated.DailyMed (U.S. National Library of Medicine)
• ColesevelamReduces glyburide exposure; give the tablets at least 4 hours before colesevelam.DailyMed (U.S. National Library of Medicine)
• AlcoholAlcohol potentiates the effect of metformin on lactate metabolism; avoid excessive intake.DailyMed (U.S. National Library of Medicine)

• Glyburide crosses the placenta and has been associated with neonatal hypoglycemia; discontinue at least two weeks before expected delivery. Metformin data are insufficient to determine a drug-associated risk; poorly controlled diabetes increases maternal and fetal risks.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Metformin is present in human milk; glyburide milk data inconclusive. Monitor breastfed infants for hypoglycemia.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Glibenclamide (glyburide): Stimulates insulin release from functioning pancreatic beta cells by binding the sulfonylurea receptor and closing ATP-sensitive potassium channels (US label).
• Metformin: Decreases hepatic glucose production, decreases intestinal glucose absorption and improves insulin sensitivity by increasing peripheral glucose uptake and utilization (US label).